Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Apr;61(4):470-3.
doi: 10.1111/j.1365-2125.2006.02592.x.

A study of codispensing with sodium alendronate in Australia

Ian W Boyd  1 , John McEwen, Lisa J Calcino
Affiliations

A study of codispensing with sodium alendronate in Australia

Ian W Boyd et al. Br J Clin Pharmacol. 2006 Apr.

Abstract

Aim: To estimate the percentage of patients dispensed alendronate who were also dispensed another drug for treatment of an upper gastrointestinal disorder ('GI' drug).

Methods: The Australian Health Insurance Commission (HIC) Pharmaceutical Benefits Scheme (PBS) database was searched to identify a cohort of patients for whom alendronate or calcitriol had been dispensed and had also been dispensed a GI drug.

Results: The number of patients dispensed a GI drug were 6.7% for alendronate and 7.5% for calcitriol with H(2)-receptor antagonists accounting for the majority of usage. This difference of - 0.8% (95% confidence interval -1.6, 0.1) is not significant.

Conclusion: There was no excess use of GI drugs in patients taking alendronate compared with those taking calcitriol and the Australian HIC PBS database is useful for identifying large numbers of patients who have been dispensed combinations of drugs.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora IIAC. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med. 1996;101:488–501. - PubMed
    1. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535–41. - PubMed
    1. Bauer DC, Black D, Ensrud K, Thompson D, Hochberg M, Nevitt M, Musliner T, Freedholm D. Upper gastrointestinal tract safety profile of alendronate. Arch Intern Med. 2000;160:517–25. - PubMed
    1. De Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK. Esophagitis associated with the use of alendronate. N Engl J Med. 1996;335:1016–21. - PubMed
    1. ADRAC. A gut feeling for alendronate. Aust Adv Drug React Bull. 1999;18:3.